Skip to main content

Table 1 Baseline characteristics

From: Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort

  GA (172) RA (480) OA (206)
Serum uric acid, mean, mmol/l (SD) 0.36 (0.14) 0.31 (0.075)** 0.31 (0.0832)**
Hyperuricaemia, n (%) 54 (32) 62 (14) 34 (17)
Uric acid lowering therapy, n (%) 126 (73) 0 0
Allopurinol, n (%) 111 (65) 0 0
Sex, n (%) male 154 (89) 133 (28)** 43 (21)**
Age, mean, years (SD) 59.6 (10.8) 59.0 (13.0) 59.2 (11.0)
Systolic blood pressure, mean, mmHg (SD) 151.0 (21.3) 144.0 (22.9)** 145.5 (20.2)**
Antihypertensive therapy, n (%) 67 (39.0) 118 (24.6) 71 (34.5)
Smoking, n (%) 43 (25) 114 (24) 38 (18)
TC/HDL ratio, mean (SD) 4.82 (1.4) 3.65 (1.1) 4.0 (1.2)
Total cholesterol, mean (SD) 5.32 (1.1) 5.30 (1.0) 5.57 (1.1)
HDL cholesterol, mean (SD) 1.17 (0.32) 1.53 (0.43) 1.48 (0.39)
Statin therapy, n (%) 22 (12.8) 32 (6.7) 26 (12.6)
Diabetes, n (%) 11 (6.4) 28 (5.8) 16 (7.8)
GlyHb, mean, % Hb (SD) 6.1 (1.4) 5.5 (1.8) 6.0 (4.2)
BMI, mean, kg/m2 (SD) 30.4 (4.7) 27.0 (4.3) 28.8 (5.3)
MDRD, mean, ml/min (SD) 80.8 (21.8) 89.9 (19.5)** 87.7 (18.7)**
NT proBNP, mean, nmol/L (SD) 37.6 (170.6) 15.9 (25.8)** 15.1 (32.8)**
hsCRP, mean, g/L (SD) 6.3 (11.2) 7.0 (10.0) 3.8 (4.9)*
Corticosteroids, n (%) 0 (0.0) 68 (14.2)¥ 1 (0.50)
  1. GA: gouty arthritis; OA: osteoarthritis; RA: rheumatoid arthritis; hsCRP: high sensitivity C-reactive protein; SD: standard deviation; CV: cardiovascular; TC: Total cholesterol; HDL: high density lipoprotein; GlyHb: glycated haemoglobin; BMI: body mass index; MDRD: modification of diet in renal disease; NT proBNP: N-terminal pro-brain natriuretic peptide. *p < 0.05 OA vs. RA and GA, **p < 0.05 RA and OA vs. GA, p < 0.05 RA vs. OA vs. GA, p < 0.05 RA vs. OA and GA., ¥p < 0.05 RA vs. GA and OA.